NIKKEI 225
26,235.17+707.80(+2.77%)HANG SENG
26,498.67+12.47(+0.05%)CRUDE OIL
43.49+0.43(+1.00%)
Atara Biotherapeutics, Inc. (0HIY.L)
| Previous close | 40.00 |
| Open | 14.95 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 14.95 - 14.95 |
| 52-week range | 14.95 - 14.95 |
| Volume | 1,300 |
| Avg. volume | N/A |
| Market cap | 371.005M |
| Beta (5Y monthly) | 2.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.53 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Company management will participate at two upcoming virtual conferences.
- Business Wire
Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual Meeting
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will present for the first time 15-month safety and efficacy data from all patients in the two highest dose cohorts of the Phase 1a open-label extension (OLE) study of ATA188 for the treatment of progressive forms of multiple sclerosis (MS). The results are featured in a poster presentation at the European Charcot Foundation (ECF) 28th Annual Meeting, held November 15-19, 2020.
- Business Wire
Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of the first preclinical evaluation of ATA3271, a next-generation, off-the-shelf, allogeneic EBV CAR T-cell therapy targeting mesothelin designed for the treatment of solid tumors. These data are being featured in a poster presentation at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020), November 11-14, 2020.
